• Sustainability
  • DE&I
  • Pandemic
  • Finance
  • Legal
  • Technology
  • Regulatory
  • Global
  • Pricing
  • Strategy
  • R&D/Clinical Trials
  • Opinion
  • Executive Roundtable
  • Sales & Marketing
  • Executive Profiles
  • Leadership
  • Market Access
  • Patient Engagement
  • Supply Chain
  • Industry Trends

Lockwood Acquires Random42 from Graphite Capital


The Lockwood Group ("Lockwood"), an industry leader in scientific-based medical communications for the pharmaceutical, biotech, and medical device industries, announced today that it has acquired Random42 ("Random42"), a best-in-class medical animation studio based in London, England from Graphite Capital. The partnership between Lockwood and Random42 expands the capabilities and geographic footprint for both organizations.

"Lockwood's commitment to innovative scientific communications is further bolstered by this addition of Random42 and the cutting-edge creative work that they do," said Lockwood Founder & CEO, Matt Schecter. "As new therapies become more and more complex the need to visualize the uniqueness of their product helps our clients differentiate their brand in a sometimes-crowded marketplace. Our customers will be astounded by the visually compelling animations, virtual reality, augmented reality, holographic, and interactive experiences created in-house by Random42's expert scientific, creative, animation, and production teams. As our clients have shared their need for imaginative solutions to breakthrough crowded markets, most recently through digital channels, we are excited to bring these inventive solutions forward immediately."

Related Videos
Related Content